New White Paper: How a Flexible Bioprocessing Platform Meets the Changing Needs of Biomanufacturing

MARLBOROUGH, MASSACHUSETTS, USA — A new white paper detailing how a flexible bioprocessing platform meets the changing needs of biomanufacturing is now available for download from Xcellerex, Inc., at http://www.xcellerex.com/flexpaper.

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These include the rise of small-market pharmaceuticals, increased titers and process productivity, the emergence of biosimilars, the evolution of healthcare reform, greater competition and tighter capital markets.

As manufacturing and facilities managers confront these challenges — and are still tasked with meeting today’s capacity needs — many are turning to a new flexible factory platform that will accelerate their implementation of biomanufacturing capacity while lowering risk, reducing time to market and reducing capital costs.

A new white paper, “The Flexible Factory Concept: A Flexible Bioprocessing Platform to Meet the Changing Needs of Biomanufacturing,” examines the approach which enables the deployment of new production capabilities in 9 to 18 months (versus 3 to 5 years for today’s technology) at a total cost of less than 50% to 80% of conventional plants.

The white paper defines the “Flexible Factory Concept” as a modular biomanufacturing platform that leverages single-use technology, controlled environment modules and advanced process automation. The paper outlines the strategic advantages and benefits of the flexible factory concept for biomanufacturers, including unequaled gains in speed to market, economics, risk mitigation, and flexibility.

Download the white paper, “The Flexible Factory Concept: A Flexible Bioprocessing Platform to Meet the Changing Needs of Biomanufacturing,” from http://www.xcellerex.com/flexpaper.

About Xcellerex, Inc.
Xcellerex, Inc. (http://www.xcellerex.com) is commercializing turnkey biomanufacturing solutions that transform the speed and economics of producing therapeutic proteins, including biosimilars and vaccines. The company’s FlexFactory® is a complete modular and portable production train based on single-use technologies, advanced process automation, and compact clean room architecture.

FlexFactory allows deployment of GMP manufacturing capacity more rapidly and at greatly reduced costs compared with traditional facilities. Through its BridgeSourcing™ services, Xcellerex manufactures a partner’s biomolecules while the partner prepares for commissioning of its own new FlexFactory. When the partner’s facility is ready, Xcellerex deploys its TransPlant™ process to install, validate and train partner personnel in their own FlexFactory. This parallel-path model both accelerates time to clinical and commercial manufacturing and allows partners to manage the development and market risks associated with adding manufacturing capacity.

Xcellerex also leverages its proprietary single-use technologies through the sale of XDR bioreactors, XDM Quad Mixers, and related single-use assemblies. To date, more than 20 therapeutic proteins and vaccines have been manufactured for clinical trials using Xcellerex technology.

Based in Marlborough, Massachusetts, Xcellerex is backed by an experienced management team and top-tier venture investors including Kleiner Perkins Caufield & Byers, VantagePoint Venture Partners and SCG Capital.

Xcellerex, Inc.
170 Locke Drive
Marlborough, MA 01752-7217
508.480.9235 Ext. 258
Press contact: Don Goncalves, Tiziani Whitmyre, 781-793-9380, dgoncalves@tizinc.com

This release was published on openPR.